Additional Insights
A well-designed IND-enabling toxicology study for advanced therapeutics and complex biologics requires precision in its terminal phase: the necropsy and tissue collection. Applying proven intelligence in preclinical toxicology ensures this final data collection step generates unambiguous, submission-ready results that accurately reflect the biological activity of a novel therapeutic candidate.
The translation of biodistribution data from animal models to human clinical application is a critical step validated by landmark clinical trials. For instance, the successful application of AAV-mediated gene therapy for inherited retinal dystrophies established AAV as a viable vector for targeted gene transfer, underscoring the importance of preclinical characterization (PMID: 18809924). This makes a properly executed necropsy necessary for generating a definitive tissue map to confirm vector tropism and assess potential off-target liabilities, providing the foundational data for clinical success.
A standardized preclinical testing template does not exist for these therapies. The necropsy protocol must be scientifically tailored to the asset modality and target indication.
- Collection Sequence: Tissues are collected in a specified order to prevent cross-contamination, which is particularly important for quantitative biodistribution assays.
- Fixation and Preservation: The choice between formalin fixation for paraffin embedding (FFPE) and snap-freezing in liquid nitrogen is dictated by the required downstream analyses, such as standard histology, immunohistochemistry (IHC), in situ hybridization (ISH), or molecular assays.
- GLP Chain of Custody: Every tissue sample is meticulously labeled, tracked, and stored under fully documented GLP conditions to ensure data integrity for regulatory review.
A foundational principle of conducting animal research is to do it right the first time, thereby ensuring no more animals are used than are absolutely required. This principle directly informs our approach to necropsy, where maximizing the data yield from every tissue sample is a primary objective.
The transition from a controlled preclinical study to the complexities of human biology is a significant analytical leap. “I think the challenge becomes transitioning from a very controlled environment to an uncontrolled environment… it’s a completely different language,” notes Dr. Naageshwaran. A properly conducted necropsy provides the foundational dataset for this translation, giving pathologists and toxicologists the high-resolution information needed to interpret safety signals and support a successful regulatory submission.
This service is a component of our comprehensive Preclinical | Translational Services.
